Prospect on medical treatment of pulmonary mucinous adenocarcinoma / 中国综合临床
Clinical Medicine of China
;
(12): 241-245, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-992497
ABSTRACT
Pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, among which invasive mucinous adenocarcinoma (IMA) is the most common subtype and is easily misdiagnosed as pneumonia. Its etiology and pathogenesis are unclear and may be related to gene mutations and other factors. Due to its relative rarity and few related studies, guidelines do not provide advices on its treatment. KRAS mutations are common in IMA patients, and Sotorasib may be effective against KRAS G12C mutated IMA. NRG1 fusion is considered to be an important driver of IMA, and afatinib may be effective in treating IMA with NRG1 fusion/rearrangement. PD-L1 expression is very low in IMA patients, while B7-H3 expression is high, so B7-H3 may be a potential immunotherapeutic target.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Clinical Medicine of China
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS